首页> 外文OA文献 >A survey on staging and treatment in uterine cervical carcinoma in the Radiotherapy Cooperative Group of the European Organization for Research and Treatment of Cancer
【2h】

A survey on staging and treatment in uterine cervical carcinoma in the Radiotherapy Cooperative Group of the European Organization for Research and Treatment of Cancer

机译:欧洲癌症研究与治疗组织放射治疗合作小组对子宫颈癌分期和治疗的调查

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

AbstractBackground: The treatment outcome of advanced stage uterine cervical carcinoma remains unsatisfactory. In order to elaborate a noveltrial within The Radiotherapy Cooperative Group (RCG) of the European Organization for Research and Treatment of Cancer (EORTC), weconducted a survey in 1997±1998 to determine the variability of pre-treatment assessment and treatment options. The variability of choosingsurgery, de®ned radiation therapy techniques and chemotherapy are investigated, as well as the center's choices of future treatment strategies.Methods: Fifty two of 81 RCG centers from the RCG have participated in the survey. As one would expect, there is a large variation in thetechniques used for pretreatment evaluation and treatment options. There is no `standard' for reporting acute and late side effects.Chemotherapy is used neither systematically nor uniformly, and some centers continue to use neadjuvant chemotherapy modalities.Results: Furthermore, the survey reveals that there is a strong demand for the reduction of overall treatment-time, for clinical investigationof novel combined modality treatment strategies, especially chemo±radiation therapy, and also for the use of new radiation sensitizers.Conclusion:We conclude that a more homogeneous approach to the pretreatment evaluation as well as treatment techniques is required inorder to allow adequate quality control in any future trial of the RCG in the EORTC.q2000 Elsevier Science Ireland Ltd. All rights reserved.
机译:摘要背景:晚期宫颈癌的治疗效果仍然不理想。为了详细研究欧洲癌症研究与治疗组织(EORTC)放射治疗合作组(RCG)的新疗法,我们于1997±1998年进行了一项调查,以确定治疗前评估和治疗方案的变异性。方法:对RCG的81个RCG中心中的52个中心参加了调查,调查了选择手术的方式,定义的放射治疗技术和化学疗法的变化以及中心对未来治疗策略的选择。正如人们所期望的,用于预处理评估和治疗选择的技术存在很大差异。没有报告急性和晚期副作用的``标准''。化学疗法未得到系统或统一使用,一些中心仍在继续使用辅助化学疗法。结果:调查还显示,强烈要求降低总体治疗时间,用于新型联合治疗策略的临床研究,尤其是化学±放射疗法,以及新放射增敏剂的使用。结论:我们得出结论,需要更均一的方法进行预处理评估和治疗技术,以便在EORTC.q2000 Elsevier Science Ireland Ltd.的RCG的任何后续试验中进行适当的质量控制。保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号